High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors.
Between November 1990 and March 1993, nine pediatric patients with newly diagnosed brain tumors having a high risk of failure with standard treatment received high-dose thiotepa/cyclophosphamide chemotherapy followed by autologous bone marrow infusion and involved-field hyperfractionated radiation therapy. The presenting diagnoses were brainstem glioma (BSG) [6], parietal mixed high-grade oligodendroglioma-astrocytoma [1], thalamic anaplastic astrocytoma [1], and high-grade parietal glioma [1]. Following chemotherapy there were two partial responses, one minor response, three with stable disease, and one with progressive disease. Responses were not evaluated in two patients who had toxic deaths. Following radiation two patients, one with brainstem glioma and one with anaplastic mixed glioma, achieved complete remission. The overall survival is no better than conventional therapy.
Kedar
A
A
Division of Pediatric Hematology-Oncology, University of Florida College of Medicine, Gainesville.
Maria
B L
BL
Graham-Pole
J
J
Ringdahl
D M
DM
Quisling
R G
RG
Mickle
J P
JP
Mendenhall
N P
NP
Marcus
R B
RB
Gross
S
S
D000293:Adolescent; D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D001933:Brain Stem; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D003520:Cyclophosphamide